Acute transverse myelitis is a rare but detrimental condition that causes paralysis. It occurs in approximately 1-8 cases per million people per year. The document discusses the diagnostic criteria and treatment options for acute transverse myelitis, which include intravenous corticosteroids such as methylprednisolone, plasma exchange, and intravenous immunoglobulin. The condition can be caused by infection or autoimmune problems and often results in permanent neurological deficits if not properly treated.

1. Ade Wijaya, MD – October 2018

2. Introduction
• Since the 19th century
• The incidence of acute transverse myelitis is given with numbers between
1:1,000,000 for the worst cases and 8:1,000,000 per year for milder sequelae
• Para- or tetraplegic
• Rare but detrimental
Greenfields JG, Norman RM. Demyelinating diseases. In: Black-wood WH, McMenemey A, Meyer, Norman RM, eds. Greenfield’s Neuropathology. Edward Arnold London; 1971:475519.
Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidenced-based guideline: clinical evaluation and treatment of transverse myelitis. Neurology. 2011;77:21282134.

3. Diagnostic
Criteria

4. Infectious
Myelopathies

5. Radiology

6. Nichtweiß M, Weidauer S. Acute Transverse Myelitis: Clinical Features, Pathophysiology, and Treatment Options. InNeuroinflammation 2018 Jan 1 (pp. 141-161). Academic Press.

7. Treatment
• IVMP: 30 mg / kg / day (max 1 gram / day) for 5 days
• PLEX
• IVIG
• Others
Nichtweiß M, Weidauer S. Acute Transverse Myelitis: Clinical Features, Pathophysiology, and Treatment Options. InNeuroinflammation 2018 Jan 1 (pp. 141-161). Academic Press.

8. Summary
• Rare but detrimental
• High morbidity
• Infectious or autoimmune
• IVMP
• PLEX / IVIG